This article examines the expanding role of GLP-1 receptor agonists in treating metabolic dysfunction-associated steatohepatitis (MASH), particularly in patients with comorbid obesity and type 2 diabetes. Despite the recent FDA approval of a dedicated MASH therapy (resmetirom), experts predict that GLP-1s will inevitably be used in hepatology due to their metabolic benefits. Clinicians emphasize the need for more specific data on liver outcomes, the potential for combination therapies, and the continued importance of lifestyle interventions.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.